An inspection of the Dr. Reddy’s Laboratories Andra Pradesh, India, facility two weeks ago brought the company yet another Form 483, this time for a lack of valid testing, failure to investigate out of specification (OOS) batches and inadequate control in manufacturing active pharmaceutical ingredients (API).
Source: Drug Industry Daily